Richard Beckman, M.D.

Richard Beckman, M.D. is Adverum’s chief medical officer (CMO) responsible for the company’s global clinical development, medical affairs and pharmacovigilance organizations. He is a board-certified ophthalmologist with over 30 years of experience in ophthalmology including in retinal diseases and glaucoma at both pharmaceutical and medical device companies. Most recently, Dr. Beckman served as the CMO at ReNeuron, Inc., where he oversaw clinical development for pipeline candidates including its human retinal progenitor cell therapy program in retinitis pigmentosa. Prior to ReNeuron, Dr. Beckman served as CMO at several companies including Clearside Biomedical, Inc., Unilife, Inc., Ophthotech, and Neurotech Pharmaceuticals, Inc. and at the latter two led clinical development programs in wet age-related macular degeneration. Previously, Dr. Beckman had roles of increasing responsibility at Alcon Research, Ltd. (acquired by Novartis), Lux BioSciences, Danube Pharmaceuticals, Inc. Becton-Dickinson, Inc., and Allergan, Inc. (acquired by AbbVie). Dr. Beckman spent ten years in private practice as a glaucoma specialist and three years in academic practice at North Shore University Hospital / Cornell University Medical College.

Dr. Beckman earned his undergraduate and medical degrees in the Integrated Premedical-Medical Program at the University of Michigan. He completed an ophthalmology residency at Henry Ford Hospital and a glaucoma fellowship at Massachusetts Eye and Ear Infirmary, a teaching hospital of Harvard Medical School.